2. Apoptosis Cell Cycle/DNA Damage
  3. Apoptosis CDK Caspase Bcl-2 Family
  4. Metuzumab

Metuzumab  (Synonyms: Licartin; Metuximab; Mehuzumab)

Cat. No.: HY-P991883
Technical Support

Metuzumab (Licartin) is a human-mouse chimeric IgG1 monoclonal antibody targeting CD147. Metuzumab induces Apoptosis, reduces levels of Cyclin D1, full-length Caspase-3, and Bcl-2, and increases Bax expression. Metuzumab enhances the sensitivity of non-small cell lung cancer (NSCLC) cells to Gemcitabine (HY-17026). Metuzumab is applicable for research on hepatocellular carcinoma and non-small cell lung cancer [1] [2].

For research use only. We do not sell to patients.

Metuzumab

Metuzumab Chemical Structure

Size Stock
1 mg   Get quote  
5 mg   Get quote  
10 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Metuzumab Related Antibodies

Top Publications Citing Use of Products

View All CDK Isoform Specific Products:

View All Isoforms
CDK1 CDK2 CDK3 CDK4 CDK5 CDK6 CDK7 CDK8 CDK9 CDK11 CDK12 CDK13 CDK14 CDK16 CDK19 CDC CLK Pho85 CDK10 CDK15 CDK17 CDK18 CDK20 PITSLRE

View All Caspase Isoform Specific Products:

View All Isoforms
Caspase 1 Caspase 2 Caspase 3 Caspase 4 Caspase 5 Caspase 6 Caspase 7 Caspase 8 Caspase 9 Caspase 10 Caspase 12 Caspase Caspase 11 Caspase-13

View All Bcl-2 Family Isoform Specific Products:

View All Isoforms
Bcl-2 Bcl-xL Bcl-W Mcl-1 Bfl-1 Bcl-B Bax Bak Bim BNIP3 Bad

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Metuzumab (Licartin) is a human-mouse chimeric IgG1 monoclonal antibody targeting CD147. Metuzumab induces Apoptosis, reduces levels of Cyclin D1, full-length Caspase-3, and Bcl-2, and increases Bax expression. Metuzumab enhances the sensitivity of non-small cell lung cancer (NSCLC) cells to Gemcitabine (HY-17026). Metuzumab is applicable for research on hepatocellular carcinoma and non-small cell lung cancer [1] [2].

Species Reactivity

Human
IC50 & Target

Caspase-3

 

Bcl-2

 

Bax

 

In Vitro

Metuzumab (0.1-100 μg/ml; 48 h) inhibits migration of SMMC-7721 cells in 2D culture in a dose-dependent manner[1].
Metuzumab (0.1-100 μg/ml; 24 h) inhibits invasion of SMMC-7721 cells in 2D Transwell assays in a dose-dependent manner[1].
Metuzumab (0.1-100 μg/ml; 48 h) inhibits proliferation of SMMC-7721 cells in 2D, 3DP, and 3DPF models in a dose-dependent manner[1].
Metuzumab (24 h) induces G1-phase arrest in A549, NCI-H460, and NCI-H520 NSCLC cells when combined with Gemcitabine, downregulating cyclin D1[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Metuzumab Related Antibodies

Cell Migration Assay[1]

Cell Line: human hepatocellular carcinoma SMMC-7721 cells (2D model)
Concentration: 0.1-100 μg/ml
Incubation Time: 48 h
Result: Decreased migration distance with increasing dose; distances for 1, 10, 100 μg/ml groups were 126.1 ± 6.7 μm, 98.8 ± 2.4 μm, 73.3 ± 8.5 μm, respectively, all significantly shorter than negative control and 0.1 μg/ml groups
In Vivo

Metuzumab (10 mg/kg; twice weekly) inhibits NSCLC tumor growth and enhances GP chemotherapy efficacy in BALB/c athymic nude mice NSCLC xenograft models (with a tumor growth inhibition of up to 91.89%)[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: BALB/c athymic nude mice (female, 5–6 weeks old)[2]
Dosage: 10 mg/kg
Administration: twice weekly
Result: Reduced tumor volume by 39.34% (A549), 36.39% (NCI-H460), and 35.18% (NCI-H520) compared to saline controls. Enhanced tumor growth inhibition to 91.89% (A549, p < 0.001 vs. GP alone), 73.99% (NCI-H460, p = 0.0001 vs. GP alone), and 69.74% (NCI-H520, p < 0.001 vs. GP alone) when combined with GP. Increased deoxycytidine kinase (dCK) expression by 2.1-fold (A549), 1.4-fold (NCI-H460), and 1.7-fold (NCI-H520) in tumor tissues (measured by IOD).
Clinical Trial
Gene ID

682  [NCBI]

Accession
Application

ELISA, FACS, Functional assay
Conjugated

Unconjugated
Reconsititution

The product can be reconstituted/diluted with sterile PBS or saline.
Formulation

Please refer to the lot-specific COA for specific buffer information.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Metuzumab Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

MetuzumabLicartin Metuximab MehuzumabApoptosisCDKCaspaseBcl-2 FamilyCyclin dependent kinaseapoptosisBcl-2full-length caspase-3A549antibody-dependent cell-mediated cytotoxicitynon-small cell lung carcinomaSMMC-7721 cellsNCI-H520Baxdeoxycytidine kinaseNSCLC xenograft modelscisplatincyclin D1gemcitabine3D co-culture microfluidic modelsNCI-H460BALB/c athymic nude miceG1 arrestCD147PBMCshepatoma cellsInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Metuzumab
Cat. No.:
HY-P991883
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.